A Phase 1/2 interventional study of MK-2750 and 5-HT3 serotonin receptor antagonist in Advanced Solid Tumors and Malignant Neoplasm, sponsored by Merck Sharp & Dohme LLC. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment
MK-2750 is a trial medicine designed to treat certain solid tumors. MK-2750 is a type of treatment called an antibody drug conjugate (ADC). ADCs attach to a protein on cancer cells and deliver medicine to destroy those cells.
The goals of this trial are to learn:
9,610 studies on the registry are indexed under Neoplasms; 2,508 are open to participants now.
This study's planned enrollment of 300 is above the median of 50 across 7,429 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,159 studies on the registry; 133 are open to participants now.
Of its 497 completed or terminated interventional studies of FDA-regulated products, 369 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive MK-2750
Biological: MK-2750 · Drug: 5-HT3 serotonin receptor antagonist · Drug: NK-1 receptor antagonist · Drug: Corticosteroid · Drug: Steroid mouthwash (dexamethasone or equivalent)
Participants will receive MK-2750
Biological: MK-2750 · Drug: 5-HT3 serotonin receptor antagonist · Drug: NK-1 receptor antagonist · Drug: Corticosteroid · Drug: Steroid mouthwash (dexamethasone or equivalent)
Administered as an intravenous (IV) infusion
Administered as a premedication per the approved product label
Administered as a premedication per the approved product label
Administered as a premedication per the approved product label
Administered orally per the approved product label as a rescue medication
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 2 years
Number of Participants Who Discontinued Study Intervention Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 2 years
Objective Response Rate (ORR)
ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by investigator will be presented.
Time frame: Up to approximately 2 years
Duration of Response (DOR)
For participants who demonstrate confirmed CR or PR per RECIST 1.1 as assessed by investigator, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.
Time frame: Up to approximately 2 years
Maximum Plasma Concentration (Cmax) of MK-2750 Free Payload
Blood samples will be collected to determine Cmax of MK-2750 Free Payload.
Time frame: Predose and at designated time points up to approximately 2 years
Cmax of MK-2750 Total Antibodies (TAb)
Blood samples will be collected to determine Cmax of MK-2750 Total Antibodies.
Time frame: Predose and at designated time points up to approximately 2 years
Cmax of MK-2750 Antibody-Drug Conjugate (ADC)
Blood samples will be collected to determine Cmax of MK-2750 Antibody-Drug Conjugate.
Time frame: Predose and at designated time points up to approximately 2 years
Trough Concentration (Ctrough) of MK-2750 Free Payload
Blood samples will be collected to determine Ctrough of MK-2750 Free Payload.
Time frame: Predose and at designated time points up to approximately 2 years
Ctrough of MK-2750 TAb
Blood samples will be collected to determine Ctrough of MK-2750 Total Antibodies.
Time frame: Predose and at designated time points up to approximately 2 years
Ctrough of MK-2750 ADC
Blood samples will be collected to determine Ctrough of MK-2750 Antibody-Drug Conjugate.
Time frame: Predose and at designated time points up to approximately 2 years
No study locations are listed for this record.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.